NCT06422741RecruitingNot Applicable
Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers With Moderate Hypercholesterolemia. Randomized, Crossover, Controlled and Triple Blind Study.(CIRCAFENOL)
Fundació Eurecat4 sites in 1 country22 target enrollmentStarted: October 28, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 22
- Locations
- 4
- Primary Endpoint
- Change in LDL cholesterol levels.
Study Overview
Brief Summary
The physiological processes of the body present daily oscillations called circadian rhythm. The circadian rhythm is essential for maintaining the vital functions of organisms, intervening directly and indirectly in a multitude of key processes, such as hormone secretion, cycles of activity and rest throughout the day, body temperature, the metabolism or absorption, processing and detoxification of nutrients. There are factors such as certain work schedules, prolonged exposure to screens, certain eating patterns or social jetlag, which have a negative impact on the circadian rhythm, causing its disruption and favoring the appearance of health alterations. Thus, there is evidence that associates night shift work with a higher incidence of risk factors for developing metabolic syndrome and cardiovascular diseases, including obesity, elevated blood levels of glucose, triglycerides, and low-density lipoprotein cholesterol (LDL-C), as well as lower levels of high-density lipoprotein cholesterol (HDL-C). In addition, disorders in the sleep cycle are associated with the development of hypertension and type 2 diabetes.
Several previous studies show that a grape seed proanthocyanidin extract (GSPE) has beneficial effects on different parameters by restoring the circadian rhythm.
Detailed Description
The main objective of the study is to evaluate the effect of daily GSPE intake, in combined with dietary recommendations, on LDL-C levels in individuals with rotating night shift work.
The secondary objectives are to evaluate the effects of GSPE on: anthropometric parameters,blood pressure, heart rate and endothelial function, markers of lipid and carbohydrate metabolism and insulin resistance, atherogenic indices, circulating levels of sex hormones and those related to hunger, satiety and stress; markers of systemic inflammation; circadian rhythm markers and sleep quality; level of physical activity, energy consumption, and changes in gene expression of key metabolic enzymes.
A randomized, crossover, placebo-controlled, triple-blind nutritional intervention study will be conducted. The study will be carried out in a population of 22 volunteers. Men and women aged 18 years or older, who are working a rotating night shift for at least 1 year and with blood levels of LDL-C between 116 and 190 mg/dL may participate.
Each volunteer will make 5 visits to the facilities of the EURECAT Nutrition and Health Technological Unit, in accordance with the study design:
- A pre-selection visit (to check inclusion/exclusion criteria), and if the inclusion criteria are met.
- Two study visits during consumption of the first product (GSPE or placebo), which will take place on the first day of study (visit 1) and after 6 weeks of treatment (visit 2).
- Two study visits during consumption of the second product (GSPE or placebo), which will take place after a three-week washout period (visit 3), and after 6 weeks of treatment (visit 4).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Men and women aged 18 years or older.
- •Follow a rotating night shift work schedule* for at least one year before the start of the study.
- •* shift workers with at least 5 night shifts per month alternating with day and/or afternoon shifts, with a seniority equal to or greater than one year.
- •Have no intention of changing the work shift during the course of the study.
- •Circulating LDL-C levels between 116 -190 mg/dL*, without pharmacological treatment with antihypertensives and/or lipid-lowering agents.
- •*Values of 116 to 190 mg/dl indicate moderate alteration in the lipid profile and a greater risk of suffering from cardiovascular diseases, according to the European Society of Cardiology, and the European Society of Atherosclerosis.
- •Have signed the informed consent before starting the study.
- •Know how to read, write and speak in Catalan or Spanish
Exclusion Criteria
- •BMI values > 30 kg/m2
- •Take supplements, multivitamin supplements (Vit.D, Vit. E and Vit.C), mineral supplements (Zinc, Selenium), essential fatty acids (omega-3), polyphenols, natural plant extracts, or phytotherapeutic products that interfere with the treatment under study.
- •Consumption of alcoholic beverages:
- •Men: consume 4 or more Standard Beverage Units daily or 28 Standard Beverage Units weekly.
- •Women: Consume 2 or more Standard Beverage Units daily or 17 Standard Beverage Units weekly.
- •Be an active smoker.
- •Having lost more than 3 kg of weight in the last 3 months.
- •Present food intolerances and/or allergies related to the study products, such as hypersensitivity to cellulose or proanthocyanidins.
- •Present any chronic or autoimmune disease in clinical manifestation that may affect the results of the study such as diabetes (type I or II), cardiovascular disease, chronic kidney disease, hyper or hypothyroidism, chronic gastrointestinal diseases or cancer.
- •Present familial hypercholesterolemia.
- •Present hypertension (Systolic ≥140 mmHg; Diastolic ≥90 mmHg)
- •Present any previous cardiovascular disease defined as myocardial infarction, angina pectoris, stroke or peripheral arterial disease.
- •Individuals with treatment in the last 3 months before the start of the study with lipid-lowering, antidiabetic and/or antihypertensive drugs, or other drugs that may interfere with the results of the study.
- •Taking supplements with polyphenol components or those aimed at lipid or blood pressure control in the last 3 months before the start of the study or during participation in the study.
- •Follow a diet to lose weight, or very restrictive types of eating, such as intermittent fasting, ketogenic diet, etc.
- •Being pregnant or intending to become pregnant.
- •Being breastfeeding.
- •Be participating or have participated in a clinical trial with medications or nutritional intervention study in the last 30 days before inclusion in the study.
- •Suffering from eating disorders or psychiatric disorders.
- •Being unable to follow study guidelines.
Outcomes
Primary Outcomes
Change in LDL cholesterol levels.
Time Frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Serum LDL cholesterol levels will be measured by commercial colorimetric kit.
Secondary Outcomes
- Height.(At week 1.)
- Change in BMI.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in waist circumference.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in the amount of body fat.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in resting heart rate.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum glucose levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum leptin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum HDL-c levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum high sensitivity c-reactive protein levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in urine 6-Sulfatoxymelatonin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Pittsburgh Sleep Quality Index.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in Physical activity.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in body weight.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in conicity index.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in the amount of bone mass.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in systolic blood pressure.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in diastolic blood pressure.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Chronotype.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in gene expression in peripheral blood mononuclear cells.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating GSPE metabolites.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in waist circumference to height ratio.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in the amount of muscle mass.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum total cholesterol levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum Triglycerides levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in LDL-c to HDL-c ratio.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in Plasma atherogenic index.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum glycosylated hemoglobin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR).(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating thyroid hormone T3 levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating estrone levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating estriol levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in the amount of total body water.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in endothelial function.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in total cholesterol to HDL-c ratio.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum insulin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum ghrelin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating testosterone levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum melatonin levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in activity and rest cycles (objective measurement).(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating thyroid hormone T4 levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in circulating 17-β-Estradiol levels.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in activity and rest cycles (subjective measurement).(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in food consumption habits.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Consumption of dietary supplements.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in body temperature.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Change in serum metabolite profile.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Adverse events(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Concomitant medication.(Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).)
- Age.(At week 1.)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Not Applicable
Effects of grape seed proanthocyanidin extract on the endothelial function in patients with stage 1 hypertensioJPRN-UMIN000030171Tokyo Medical and Dental University30
Completed
Not Applicable
Circadian Modulation of Grape Consumption and Oxidative Stress ResponseOxidative StressNCT05873530Idaho State University32
Completed
Not Applicable
Effect of Grape Seed Extract on Blood PressureElevated Blood PressureNCT00869193Unilever R&D70
Completed
Phase 2
Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical UseAtherosclerosis of Arteries of the Extremities, UnspecifiedNCT01707615Jie Qiu287
Completed
Not Applicable
Ability of Grape Seed Proanthocyanidins to Reduce Postprandial Triglycerides in HumansTriglyceride MetabolismCardiovascular FunctionNCT01688154Technological Centre of Nutrition and Health, Spain16